As soon as possible to control blood pressure, the majority of Stethoscope hypertensive patients from the initial stage of treatment on the choice of a joint administration, which has become a trend in the treatment of hypertension.
This is the People's Hospital of Peking University Xu Chengbin professor of internal medicine in a few days ago the "2008 International Society of Hypertension in China," Symposium on that point of view.
This reporter has learned, hypertension, cardiovascular disease would be the risk of increases. Reduce cardiovascular disease in one of the key target is to buck. "However, China's pressure-relief situation is not optimistic target. National survey data show that prevalence of hypertension in China has reached 18.8 percent, the buck does not target patients account for about 94 percent." Xu Chengbin said. "To achieve relief purposes, usually relying on a drug is not enough." Xu Chengbin said that in China, more than two-thirds of hypertensive patients Stethoscope need to take two or more drugs to control blood pressure. Now more and more doctors recommended that the initial treatment of patients with hypertension should be on stage with two or more antihypertensive drugs in the treatment, which will help control blood pressure as early as possible, so as to achieve the maximum reduction of cardiovascular morbidity and mortality.
Xu Chengbin, a joint ACEI (angiotensin-converting enzyme inhibitors) for the 2007 European hypertension treatment guidelines recommend one of the preferred relief programme. A new generation of ACEI Mengnuo can not only help hypertension standards, reduce cardiovascular events in patients with coronary heart disease and the death of long-term risks, but also play a role in the protection of the kidney.